MANILA, Philippines - TelAve -- The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) says the U.S. Food and Drug Administration's decision to authorize reduced-risk claims for specific nicotine pouch products should prompt a policy rethink across Asia Pacific.

CAPHRA says too many governments in the region still treat cigarettes, high-risk smokeless tobacco, and smoke-free nicotine products as if they carry the same risk, even though that approach distorts regulation and misleads consumers.

The FDA has authorized nicotine pouch products to be marketed with a specific modified-risk claim stating that using them instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.

Nancy Loucas, Executive Coordinator of CAPHRA, said the ruling should be closely studied by regulators across the region.  "This is what risk-proportionate regulation looks like," Loucas said. "The FDA has not said nicotine pouches are harmless. It has recognized that for adults who would otherwise smoke, specific scientifically reviewed products can reduce risk. That is the kind of regulatory honesty many Asia Pacific governments still avoid."

More on TelAve News

• Wagga Trucks set to expand to the Canberra Region as authorised dealer for Volvo, UD & Mack along with Freighter Group Trailers
• June Employment Report Reveals Hidden Weakness Beneath Lower Unemployment
• Phinge Home Of Netverse, Is Actively Investigating The "Model Context Protocol" (MCP) For Infringement Of Its IP From Its June, 2021 Priority Dates
• Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules
• Why More Phoenix Families Are Turning to Private Autopsy Services for Answers

CAPHRA said this matters especially in South and Southeast Asia, where smokeless tobacco use is already widespread and remains a major health burden.  Prevalence studies in Bangladesh, India, and Myanmar have found smokeless tobacco use is highest among men and in rural communities.

The group said oral nicotine policy therefore cannot be treated as a niche issue. In a region where millions already use oral tobacco, refusing to distinguish between high-risk traditional products and lower-risk modern alternatives is not caution - it is poor public health design. For adults who already use cigarettes or high-risk oral tobacco, access to accurate information and lower-risk alternatives can be the difference between continued exposure and meaningful harm reduction.

CAPHRA said it supports strict youth protections, strong product standards, and tough enforcement against underage sales. But it warned that public health credibility is damaged when governments continue to tolerate cigarettes and entrenched high-risk oral tobacco while refusing to evaluate lower-risk smoke-free alternatives on the basis of relative risk.

More on TelAve News

• Make America French Again Launches National Campaign
• RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
• 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
• Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area
• Slotozilla Introduces a Centralized Resource for World Cup Bonus Offers

CAPHRA is calling on Asia Pacific governments to review the FDA's findings, regulate oral nicotine products according to evidence and relative risk, enforce strict youth access controls, require robust product standards, and ensure that adults receive accurate information about comparative harms. The group said the test for policymakers is simple: regulate by evidence and relative risk, not by ideology or by treating all nicotine products as interchangeable.

"In a region where oral tobacco use is already widespread, refusing to evaluate lower-risk nicotine alternatives is not precaution, it is a policy choice to leave more dangerous products unchallenged."